Abstract
IntroductionMost patients with oesophageal adenocarcinoma (OA) are unfit for curative treatment but are fit for photodynamic therapy (PDT). PDT has been limited by poor tumour selectivity, poor tissue penetration of...
Highlights
Patients with Barrett’s (BE) associated oesophageal adenocarcinoma (OA), show strong expression of the mucin MUC1, but binding is not specific to dysplasia or cancer
34 paraffin embedded oesophageal tissue specimens were selected from patients with squamous (n1⁄45), non-dysplastic BE (NDBE; n1⁄43), low grade dysplasia (LGD; n1⁄46), high grade dysplasia (HGD; n1⁄49) and OA (n1⁄411)
Nonsignificant mild staining was seen in NDBE (100%), LGD (33%), HGD (44%) and OA (64%)
Summary
Most patients with oesophageal adenocarcinoma (OA) are unfit for curative treatment but are fit for photodynamic therapy (PDT). PDT has been limited by poor tumour selectivity, poor tissue penetration of light and protracted side effects. These restrictions may be overcome with targeted PDT. Results HuHMFG1:PPa PICs, well conjugated by fluorescent photography of SDS-page gels, were very insoluble. Further characterisation was limited to PS1 PICs. UV/Vis analysis of the soluble HuHMFG1:PS1 PIC supernatant, suitable for subsequent in vitro testing, confirmed maximum absorption at 683 nm (Abstract PWE-012 figure 1). SDS page analysis indicated up to 52% of PS1 photosensitiser was conjugated in the supernatant mixture postdialysis. AIDA image analysis confirmed that in those antibodies conjugated, a loading ratio of PS1:HuHMFG1 of up to 7:1 was achieved
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
